NIH Grants $2M to Path Fertility for Epigenetic Male Infertility Test

The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has awarded Path Fertility, the commercial brand of Inherent Biosciences, Inc., a two-year, $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant. The award, designated R44HD121294, was announced on October 26, 2026, and will fund development and clinical validation of an epigenetic diagnostic for non-obstructive azoospermia (NOA) — the most severe form of male infertility — and its associated cancer risk. For government contracting professionals, the award represents a targeted federal investment in translational biotechnology and reproductive-health diagnostics, delivered through the SBIR mechanism rather than an open procurement solicitation. There is no bidding opportunity or deadline attached to this signal; it is a funded research effort and a reference point for the diagnostics market.

NOA affects roughly 1% of men worldwide and is linked to higher risks of cancer and cardiovascular disease. Current tests, including karyotyping and Y-chromosome microdeletion testing, leave many cases without an explanation. Prior research by Dr. Dolores Lamb and collaborators, supported by Inherent Biosciences, found epigenetic changes — termed "epimutations" — in MSH5, a DNA repair gene, in up to 19% of men with NOA. That finding points to a molecular pathway that may explain a significant share of otherwise unexplained cases and connects spermatogenic failure to broader health risks. The new NICHD award is intended to move that research toward clinical and commercial validation.

Under the award, Path Fertility will pursue several defined activities: confirming how often MSH5 epimutations occur in a broader group of men with NOA through a multi-site clinical study; developing a semen-based reflex test that removes the need for a separate blood draw; measuring MSH5 epimutations in 500 patients with colorectal cancer, a population known for DNA mismatch repair defects; and validating the assay in a CLIA-certified laboratory for commercial launch as a laboratory developed test. The test will be incorporated into NOA Guide, Path Fertility's diagnostic that helps predict whether sperm can be retrieved surgically in men with NOA. NOA Guide also uses the sperm-derived cell-free DNA technology that Path Fertility further developed under a prior NICHD SBIR grant and is presenting at the ASRM 2026 Scientific Congress & Expo in Baltimore.

The award carries several implications for biotech contractors and SBIR applicants. First, it demonstrates federal willingness to fund late-stage diagnostic validation, including multi-site clinical studies and CLIA-laboratory work — a scope that can serve as a template for clinical-stage SBIR proposals. Second, it highlights reproductive-health biotechnology as an area of active federal R&D support, even absent a standing procurement vehicle. Third, the inclusion of a 500-patient colorectal cancer cohort shows how diagnostic developers can bridge fertility and oncology indications to strengthen clinical evidence and commercial positioning. The announcement coincides with the ASRM 2026 Scientific Congress & Expo, where Path Fertility Chief Scientific Officer Kristin Brogaard, Ph.D., is presenting two studies, including new data showing sperm epigenetics predicts IUI success across clinics and physicians, and that sperm-derived cell-free DNA predicts sperm retrieval outcomes in men with azoospermia.

For GovCon intelligence purposes, the key distinction is that this is an award, not a solicitation. Companies tracking NIH SBIR opportunities should note the Direct to Phase II pathway, which allows small businesses with prior feasibility data to skip Phase I and compete directly for Phase II funding. The scope here — multi-site research, a defined patient cohort, and CLIA validation — is consistent with the type of translational work NICHD and other NIH institutes support. Vendors in laboratory services, clinical trial management, and diagnostic validation may find downstream subcontracting or partnership opportunities, though none are announced in this award. The award also reinforces the strategic value of epigenetic biomarkers in federal research portfolios, particularly where a single assay can address multiple disease areas.

• NIH/NICHD awarded a two-year, $2 million Direct to Phase II SBIR grant (R44HD121294) to Path Fertility, the commercial brand of Inherent Biosciences, Inc.
• The funded diagnostic targets non-obstructive azoospermia (NOA), which affects roughly 1% of men worldwide and is linked to cancer and cardiovascular risk
• Prior research found MSH5 epimutations in up to 19% of men with NOA, connecting spermatogenic failure to broader health risks
• Award scope includes a multi-site clinical study, a semen-based reflex test, testing in 500 colorectal cancer patients, and CLIA-certified laboratory validation
• The test will integrate into NOA Guide, which uses sperm-derived cell-free DNA technology developed under a prior NICHD SBIR grant
• Announcement coincides with the ASRM 2026 Scientific Congress & Expo in Baltimore, where CSO Kristin Brogaard, Ph.D., is presenting two studies
• This is an award, not a solicitation; no procurement deadline or bidding opportunity is attached
• The Direct to Phase II pathway allows small businesses with prior feasibility data to compete directly for Phase II funding, a model relevant to clinical-stage diagnostic developers